PRESS RELEASE Ergomed strongly positioned for future growth in new partnership with Permira Permira completes acquisition of Ergomed for £703.1 millionThrough this partnership, Permira will support...
Shares of Granules India have rallied 7% to Rs 104 per share on the BSE in early morning trade after the pharmaceuticals company said Granules Pharmaceuticals Inc., a wholly owned subsidiary of the company, received US health regulatory approval for generic Methylergonovine tablets.
Granules India Ltd. announced that the US FDA has approved its Abbreviated New Drug Applications (ANDA) for methylergonovine 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India Limited. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 mg.
Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergin®, a product owned by Edison Therapeutics, LLC. and is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage. Breckenridge is launching this product in conjunction with the ANDA holder, Ergoject, LLC.
: Drug major Lupin is looking to strengthen its branded and specialty business in the US by launching new products, brand acquisitions and even buyout of other specialty companies which compliment its therapy focus.
Ergomed Announces Co-Development Agreement with Dilaforette for Sickle-Cell Disease Treatment